Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Repisalud
Publication Carta al director (LetterToTheEditor)

Impact of Cumulative Sleep Duration on Cardiac Structural Remodeling in Asymptomatic Adolescents.

  • Real, Carlos
  • Párraga, Rocío
  • Martínez-Gómez, Jesús
  • Beneito-Dura, María
  • González-Calvo, Ernesto
  • Diaz-Munoz, Raquel
  • Fernández-Acín, Paula
  • Gutierrez-Ortiz, Eva
  • Garcia-Cocera, Miriam
  • Sánchez-González, Javier
  • Pizarro, Gonzalo
  • García-Lunar, Inés
  • Galán-Arriola, Carlos
  • Fernández-Alvira, Juan Miguel
  • De Miguel, Mercedes
  • de Cos-Gandoy, Amaya
  • Bodega, Patricia
  • Pérez de Isla, Leopoldo
  • Fernandez-Ortiz, Antonio
  • Ibáñez, Borja
  • Santos-Beneit, Gloria
  • Fuster, Valentín
  • Fernández-Jiménez, Rodrigo
Repisalud
Publication Artículo científico (JournalArticle)

Metoprolol blunts the time-dependent progression of infarct size

  • Lobo-Gonzalez, Manuel
  • Galan-Arriola, Carlos
  • Rossello, Xavier
  • González-Del-Hoyo, Maribel
  • Vilchez, Jean Paul
  • Higuero-Verdejo, María I
  • Garcia-Ruiz, Jose M
  • Lopez-Martin, Gonzalo J.
  • Sanchez-Gonzalez, Javier
  • Oliver, Eduardo
  • Pizarro, Gonzalo
  • Fuster, Valentin
  • Ibáñez, Borja
Early metoprolol administration protects against myocardial ischemia-reperfusion injury, but its effect on infarct size progression (ischemic injury) is unknown. Eight groups of pigs (total n = 122) underwent coronary artery occlusion of varying duration (20, 25, 30, 35, 40, 45, 50, or 60 min) followed by reperfusion. In each group, pigs were randomized to i.v. metoprolol (0.75 mg/kg) or vehicle (saline) 20 min after ischemia onset. The primary outcome measure was infarct size (IS) on day7 cardiac magnetic resonance (CMR) normalized to area at risk (AAR, measured by perfusion computed tomography [CT] during ischemia). Metoprolol treatment reduced overall mortality (10% vs 26%, p = 0.03) and the incidence and number of primary ventricular fibrillations during infarct induction. In controls, IS after 20-min ischemia was ≈ 5% of the area AAR. Thereafter, IS progressed exponentially, occupying almost all the AAR after 35 min of ischemia. Metoprolol injection significantly reduced the slope of IS progression (p = 0.004 for final IS). Head-to-head comparison (metoprolol treated vs vehicle treated) showed statistically significant reductions in IS at 30, 35, 40, and 50-min reperfusion. At 60-min reperfusion, IS was 100% of AAR in both groups. Despite more prolonged ischemia, metoprolol-treated pigs reperfused at 50 min had smaller infarcts than control pigs undergoing ischemia for 40 or 45 min and similar-sized infarcts to those undergoing 35-min ischemia. Day-45 LVEF was higher in metoprolol-treated vs vehicle-treated pigs (41.6% vs 36.5%, p = 0.008). In summary, metoprolol administration early during ischemia attenuates IS progression and reduces the incidence of primary ventricular fibrillation. These data identify metoprolol as an intervention ideally suited to the treatment of STEMI patients identified early in the course of infarction and requiring long transport times before primary angioplasty.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease

  • Muñoz-Delgado, Laura
  • Labrador, Miguel Ángel
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Benítez Zamora, Belén
  • Fernández-Rodríguez, Paula
  • Adarmes-Gómez, Astrid
  • Reina-Castillo, María Isabel
  • Castro-Labrador, Sandra
  • Silva-Rodríguez, Jesús
  • Carrillo, Fátima
  • García-Solís, David
  • Grothe, Michel J.
  • Mir, Pablo
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background] Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil-to-lymphocyte ratio (NLR) is a well-established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP-CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density., [Objectives] To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD., [Methods] We assessed clinical features, the peripheral immune profile, and striatal [123I]FP-CIT DAT binding levels of 211 patients with PD (primary-cohort). Covariate-controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI-cohort)., [Results] A higher NLR was significantly associated with lower DAT levels in the caudate (primary-cohort: β = −0.01, p < 0.001; PPMI-cohort: β = −0.05, p = 0.05) and the putamen (primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary-cohort: β = +0.09, p < 0.05; PPMI-cohort: β = +0.11, p = 0.02) and the putamen (primary-cohort: β = +0.09, p < 0.05, PPMI-cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = 0, p = 0.94; putamen; primary-cohort: β = −0.04, p = 0.08; PPMI-cohort: β = −0.01, p = 0.73)., [Conclusions] Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía. Grant Numbers: CTS-7685, CVI-02526, Consejería de Salud y Bienestar Social de la Junta de Andalucía. Grant Numbers: PE-0186-2019, PE-0210-2018, PI-0459-2018, PI-0471-2013, Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía. Grant Number: PY20_00896, Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). Grant Numbers: PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease

  • Muñoz-Delgado, Laura
  • Macías García, Daniel
  • Periñán, María Teresa
  • Jesús Maestre, Silvia
  • Adarmes-Gómez, Astrid
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Jiménez-Jaraba, María Valle
  • Benítez Zamora, Belén
  • Díaz-Belloso, Rafael
  • García-Díaz, Sergio
  • Martín Bórnez, Miguel
  • Pineda-Sánchez, Rocío
  • Carrillo, Fátima
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms., The authors thank the donors and the Hospital Universitario Virgen del Rocío-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for the human specimens used in this study. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, and PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases – Project ID No 739510. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017; from the Andalusian Regional Ministry of Health). Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias, Junta de Andalucía (B-0007-2019). Daniel Macías-Garcia was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III. Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III. Rafael Díaz Belloso was supported by pre-doctoral contract for training in health research (PFIS) from Instituto de Salud Carlos III. Sergio García Díaz was supported by an University Teacher Training Programme (FPU) from the Spanish Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Data-driven characterization of distinct cognitive subtypes in Parkinson's disease dementia

  • Labrador-Espinosa, Miguel
  • Silva-Rodríguez, Jesús
  • Mir, Pablo
  • Grothe, Michel J.
Data used in the preparation of this study were obtained from the Parkinson’s Progression Markers Initiative database, which is publicly available to interested researchers (www.ppmi-info.org)., Individual cognitive profiles of patients with Parkinson's disease dementia (PDD) are highly heterogeneous, suggesting possible biological subtypes. We studied 75 PD patients who developed dementia in the course of the Parkinson's Progression Markers Initiative study to investigate data-driven evidence for the existence of distinct cognitive subtypes of PDD. Using Ward's hierarchical clustering on neuropsychological test data, we identified two distinct cognitive subtypes. Despite similar dementia severity (MoCA: 20.6 vs 20.0), cluster-A exhibited more pronounced memory deficits (n = 50), whereas cluster-B showed greater visuospatial impairments (n = 25). The subtypes did not differ in demographic, motor, or MRI-based neurodegeneration measures. However, the visuospatial-predominant cluster-B had a higher prevalence of GBA mutations (p = 0.003) and hallucinations (p = 0.009). No differences were found in APOE-ε4 prevalence or cerebrospinal fluid biomarkers of Alzheimer's pathology. These findings reveal distinct memory-predominant and visuospatial-predominant PDD subtypes, which associate with different clinical and genetic features but are independent of comorbid Alzheimer's pathology., Data used in the preparation of this manuscript were obtained from the Parkinson’s Progression Markers Initiative database (www.ppmi-info.org/data). For up-to-date information on the study visit www.ppmi-info.org. Parkinson’s Progression Markers Initiative—a public-private partnership—is funded by The Michael J. Fox Foundation for Parkinson’s Research. Corporate funding partners include AbbVie, Allergan, Amathus, Avid, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Janssen Neurosciene, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager, and the philanthropic funding partner is Golub Capital. This work was supported by research grants from the Spanish Ministry of Science, Innovation and Universities (CNS2024-154295; RYC2023-043746-I), the Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (ISCIII-FEDER: PI22/01704; PI24/00089; CP19/00031), and the Reina Sofia Foundation (E.6.4 FRS-CUERPOS DE LEWY)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease

  • Diaz-Galván, Patricia
  • Franco-Rosado, Pablo
  • Silva-Rodríguez, Jesús
  • Castro-Labrador, Sandra
  • Labrador, Miguel Ángel
  • Muñoz-Delgado, Laura
  • Grothe, Michel J.
  • Mir, Pablo
[Data Availability] All clinical data and raw MRI scans used in this study are available in the PPMI database.30 The identity (ID) numbers of the participants included in this study, the MRI data before processing, and R scripts for statistical analyses in this study will be made available on request to facilitate replication of the findings., [Background and Objectives] Accumulating evidence suggests that physical activity is associated with a better clinical and cognitive course in Parkinson disease (PD), yet whether these effects are subserved by structural brain alterations are largely unexplored. The aim of this study was to investigate whether regular physical activity associates with a reduced longitudinal rate of neurodegeneration and slower cognitive decline in PD., [Methods] In this longitudinal, observational cohort study, we used data from the Parkinson's Progression Markers Initiative. We included patients with early PD who had serial assessments of regular physical activity, measured using the Physical Activity Scale for the Elderly, along with serial MRI scans from at least 2 time points over 4 years of follow-up. Regional cortical thickness and subcortical volumes were calculated using established procedures. We used multivariate linear mixed-effects models to analyze the effect of regular physical activity on the progression of MRI parameters over time. We further used mediation models with nonparametric bootstrap to test mediation effects of longitudinal structural brain changes on the association between regular physical activity and longitudinal cognitive functioning., [Results] A total of 120 patients with early PD were included (mean [SD] age = 60.8 [9.3] years; 33% women). Average regular physical activity levels over time were significantly associated with slower cortical thinning in temporoparietal cortical regions, including the lateral temporal cortex, the fusiform gyrus, the parahippocampal gyrus, and the inferior parietal cortex (p < 0.05). Regular physical activity levels over time were also associated with slower volume loss in the hippocampus and the amygdala (p < 0.05). The association of regular physical activity with slower decline in memory and attention functions was mediated by slower decreases in temporoparietal cortical thickness (βPASE-HVLT, = 0.06, p = 0.050; βPASE-SDMT = 0.04, p = 0.017) and hippocampal volume (βPASE-SDMT = 0.03, p = 0.016)., [Discussion] Regular physical activity is associated with a slower rate of neurodegeneration in the temporoparietal cortex and limbic areas in PD, which contributes to preserved cognitive function and improved long-term outcomes. This supports regular physical activity as a key intervention to delay disease progression and improve quality of life in patients with PD., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), funded by the Instituto de Salud Carlos III and co-funded by the European Union (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512); the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685); the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019); the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022); the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896, PY20_00903); and the Alicia Koplowitz Foundation. MJG is supported by the “Miguel Servet” program of the ISCIII-FEDER (CP19/00031)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

EEG changes induced by dopamine replacement therapy in Parkinson’s disease with impulse control disorders

  • Martín-Rodríguez, Juan Francisco
  • Iglesias Camacho, Elena
  • Gómez-Campos, Francisco Javier
  • Franco-Rosado, Pablo
  • Garrote-Espina, Lorena
  • Muñoz-Delgado, Laura
  • Jesús Maestre, Silvia
  • Macías García, Daniel
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
[Objectives] Impulse control disorders (ICDs) are a common complication in Parkinson’s disease (PD) patients undergoing dopaminergic therapy. Although neurophysiological markers of ICDs have been identified, the effect of dopaminergic therapy on these markers is not fully understood. This study investigates the effect of dopaminergic therapy on EEG oscillatory activity in PD patients with and without ICDs., [Methods] A total of 26 PD patients—14 with ICDs (PD + ICD) and 12 healthy controls (HC)—participated. EEG recordings were obtained during regular dopamine therapy (ON) and after overnight withdrawal (OFF). Spectral analysis assessed group differences in EEG activity and the effect of dopaminergic treatment, while correlations between neurophysiological parameters and impulsivity were analysed., [Results] Results showed increased theta power (4–7.5 Hz) in the fronto-central regions of PD+ICD patients in the OFF state compared to healthy controls. In the ON state, PD+ICD patients showed increased frontal high beta (21–30 Hz) and central alpha (8–12 Hz) activity. Frontal beta activity correlated with impulsivity, independent of treatment dose., [Conclusions] PD + ICD patients show distinct neurophysiological profiles influenced by dopaminergic treatment, highlighting the modulatory effect of therapy on EEG patterns in these patients., [Significance] This study highlights the modulatory effect of dopaminergic therapy on EEG oscillatory patterns in PD patients with ICDs., We are very grateful to the individuals who participated in this study. This work was supported by a Grant PID2021-127034OA-I00 funded by MCIN/AEI/10.13039/501100011033 and, by “ERDF A way of making Europe”, the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI22/01704), the Fundación Progreso y Salud (PI-0055-2014), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformacion Economica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00903), and the Fundacion Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (project ID 739510). L.M.D. and P.M.R. are members of the COST Action IMMUPARKNET (CA21117). D.M.G. was supported by the “Juan Rodés” program [JR22/00073] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Co-prescription patterns of cardiovascular preventive treatments: A cross-sectional study in the Aragon worker' health study (Spain)

  • Aguilar-Palacio, I.
  • Malo, S.
  • Lallana, M.
  • Feja, C.
  • González, J.
  • Moreno-Franco, B.
  • Rabanaque, M.
Objectives: To identify cardiovascular disease (CVD) preventive treatments combinations, among them and with other drugs, and to determine their prevalence in a cohort of Spanish workers. Design: Cross-sectional study. Setting Aragon Workers'' Health Study (AWHS) cohort in Spain. Participants 5577 workers belonging to AWHS cohort. From these subjects, we selected those that had, at least, three prescriptions of the same therapeutic subgroup in 2014 (n=4605). Primary and secondary outcome measures Drug consumption was obtained from the Aragon Pharmaceutical Consumption Registry (Farmasalud). In order to know treatment utilisation, prevalence analyses were conducted. Frequent item set mining techniques were applied to identify drugs co-prescription patterns. All the results were stratified by sex and age. Results: 42.3% of men and 18.8% of women in the cohort received, at least, three prescriptions of a CVD preventive treatment in 2014. The most prescribed CVD treatment were antihypertensives (men: 28.2%, women 9.2%). The most frequent association observed among CVD preventive treatment was agents acting on the renin-angiotensin system and lipid-lowering drugs (5.1% of treated subjects). Co-prescription increased with age, especially after 50 years old, both in frequency and number of associations, and was higher in men. Regarding the association between CVD preventive treatments and other drugs, the most frequent pattern observed was lipid-lowering drugs and drugs used for acid related disorders (4.2% of treated subjects). Conclusions: There is an important number of co-prescription patterns that involve CVD preventive treatments. These patterns increase with age and are more frequent in men. Mining techniques are a useful tool to identify pharmacological patterns that are not evident in the individual clinical practice, in order to improve drug prescription appropriateness.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

  • Aguilar Palacio, Isabel
  • Rabanaque Hernández, María José
  • Maldonado, Lina
  • Chaure, Armando
  • Abad-Díez, José María
  • León-Latre, Montse
  • Casasnovas, José Antonio
  • Malo, Sara
The objective of this study was to analyse persistence to lipid-lowering drug use for primary prevention of cardiovascular disease (CVD) in a new users cohort, to explore all-cause and cardiovascular related morbidity, comorbidity and mortality in this group and, finally, to study the relationship between persistence and morbimortality. We selected subjects who started lipid-lowering treatment for primary prevention of CVD between 1 January 2010 and 31 December 2017 (N = 1424), and classified them as treatment-persistent or -nonpersistent. Bivariate analyses were performed to compare sociodemographic and clinical variables, morbimortality and time to event between groups. The association between morbidities was explored using comorbidity network analysis. The effect of persistence was analysed using logistic regression and Cox survival analyses. Only 38.7% of users were persistent with treatment. Persistent and nonpersistent users had similar sociodemographic and clinical profiles, although differed in age, smoking status, and glycemia. Comorbidity networks revealed that the number of co-occurring diagnoses was higher in nonpersistent than persistent users. Adjusted analyses indicated a protective effect of treatment persistence, especially against major adverse cardiovascular events (MACE), but this effect was not statistically significant. Observational studies are crucial to characterize real-world effectiveness.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Factors Associated with the Prescribing of High-Intensity Statins

  • Chaure-Pardos, Armando
  • Malo, Sara
  • Rabanaque, María José
  • Arribas, Federico
  • Moreno-Franco, María Belén
  • Aguilar-Palacio, Isabel
In this study, we investigated the relationship between sociodemographic, clinical, anthropometric, and lifestyle characteristics and the type of statin prescribed for primary prevention of cardiovascular disease (CVD). We conducted an observational study in workers who began statin treatment. Statin therapy was categorized as "high-intensity" or "low-moderate-intensity". Workers were classified according to the alignment of their statin therapy with the recommended management practices. Logistic regression models were used to evaluate the association between the different variables studied and the probability of being prescribed high-intensity statins. The only variables associated with a higher probability of being treated with high-intensity statins were increased physical activity (>40 versus <20 METs (metabolic equivalent of task) h/wk; odds ratio (OR), 1.65; 95%CI, 1.08-2.50) and, in diabetics, higher low-density lipoprotein cholesterol (LDL-C) levels (>= 155 mg/dL versus <155 mg/dL; OR, 4.96; 95%CI, 1.29-19.10). The model that best predicted treatment intensity included LDL-C, diabetes, hypertension, smoking, and age (area under the Receiver Operating Characteristic curve (AUC), 0.620; 95%CI, 0.574-0.666). The prescribing and type of statin used in primary CVD prevention did not correspond with the indications in current guidelines. The probability of receiving high-intensity statins was higher in diabetics with high LDL-C levels and in more physically active individuals. These findings underscore the great variability and uncertainty in the prescribing of statins.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Identifying clusters of adherence to cardiovascular risk reduction behaviors and persistence with medication in new lipid-lowering drug users. Impact on healthcare utilization

  • Malo, Sara
  • Rabanaque, María José
  • Maldonado, Lina
  • Moreno-Franco, Belén
  • Chaure-Pardos, Armando
  • Lallana, María Jesús
  • Rodrigo, María Pilar
  • Aguilar-Palacio, Isabel
We sought to identify specific profiles of new lipid-lowering drug users based on adherence to a healthy lifestyle and persistence with medication, and to characterize co-morbidities, co-treatments, and healthcare utilization for each of the profiles identified. Observational study in 517 participants in the Aragon Workers’ Health Study (AWHS) without previous cardiovascular disease (CVD) and who initiated lipid-lowering therapy. Data were collected from workplace medical examinations and administrative health databases (2010– 2018). Using cluster analysis, we identified distinct patient profiles based on persistence with therapy and lifestyle. We then compared characteristics, morbidity, and healthcare utilization across clusters. Participants were aggregated into four clusters based on persistence with therapy, smoking status, adherence to Mediterranean diet, and physical activity. In cluster 1 (n = 113), comprising those with a healthiest lifestyle (14.2% smokers, 84.0% with medium-high adherence to Mediterranean diet, high physical activity), 16.8% were persistent. In cluster 3 (n = 108), comprising patients with the least healthy lifestyle (100% smokers, poor adherence to the Mediterranean diet, low level of physical activity), all were non-persistent. Clusters 2 (n = 150) and 4 (n = 146) both comprised patients with intermediate lifestyle be-haviors, but differed in terms of persistence (100 and 0%, respectively). Compared with other clusters, the burden of morbidity, cardiovascular score, and healthcare utilization were lower in cluster 1. The healthy adherer effect was only observed in new lipid-lowering drug users of certain profiles. Furthermore, we found that differences in adherence to lifestyle and medication recommendations for CVD prevention influenced morbidity burden and healthcare utilization.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effectiveness of Statins for Primary Prevention of Cardiovascular Disease in Low- and Medium-Risk Males: A Causal Inference Approach with Observational Data

  • Chaure-Pardos, Armando
  • Aguilar-Palacio, Isabel
  • Rabanaque, Mª José
  • Lallana, Mª Jesús
  • Maldonado, Lina
  • Castel-Feced, Sara
  • Librero, Julián
  • Casasnovas, José Antonio
  • Malo, Sara
In this study, we analyzed the effectiveness of statin therapy for the primary prevention of cardiovascular disease (CVD) in low- and medium-risk patients. Using observational data, we estimated effectiveness by emulating a hypothetical randomized clinical trial comparing statin initiators with statin non-initiators. Two approaches were used to adjust for potential confounding factors: matching and inverse probability weighting in marginal structural models. The estimates of effectiveness were obtained by intention-to-treat and per-protocol analysis. The intention-to-treat analysis revealed an absolute risk reduction of 7.2 (95% confidence interval (CI95%), −6.6–21.0) events per 1000 subjects treated for 5 years in the matched design, and 2.2 (CI95%, −3.9–8.2) in the marginal structural model. The per-protocol analysis revealed an absolute risk reduction of 16.7 (CI95%, −3.0–36) events per 1000 subjects treated for 5 years in the matched design and 5.8 (CI95%, 0.3–11.4) in the marginal structural model. The indication for statin treatment for primary prevention in individuals with low and medium cardiovascular risk appears to be inefficient, but improves with better adherence and in subjectvs with higher risk.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Influence of cardiovascular risk factors and treatment exposure on cardiovascular event incidence: assessment using machine learning algorithms

  • Castel-Feced, Sara
  • Malo, Sara
  • Aguilar-Palacio, Isabel
  • Feja-Solana, Cristina
  • Casasnovas, José Antonio
  • Maldonado, Lina
  • Rabanaque-Hernández, María José
Assessment of the influence of cardiovascular risk factors (CVRF) on cardiovascular event (CVE) using machine learning algorithms offers some advantages over preexisting scoring systems, and better enables personalized medicine approaches to cardiovascular prevention. Using data from four different sources, we evaluated the outcomes of three machine learning algorithms for CVE prediction using different combinations of predictive variables and analysed the influence of different CVRF-related variables on CVE prediction when included in these algorithms. A cohort study based on a male cohort of workers applying populational data was conducted. The population of the study consisted of 3746 males. For descriptive analyses, mean and standard deviation were used for quantitative variables, and percentages for categorical ones. Machine learning algorithms used were XGBoost, Random Forest and Naïve Bayes (NB). They were applied to two groups of variables: i) age, physical status, Hypercholesterolemia (HC), Hypertension, and Diabetes Mellitus (DM) and ii) these variables plus treatment exposure, based on the adherence to the treatment for DM, hypertension and HC. All methods point out to the age as the most influential variable in the incidence of a CVE. When considering treatment exposure, it was more influential than any other CVRF, which changed its influence depending on the model and algorithm applied. According to the performance of the algorithms, the most accurate was Random Forest when treatment exposure was considered (F1 score 0.84), followed by XGBoost. Adherence to treatment showed to be an important variable in the risk of having a CVE. These algorithms could be applied to create models for every population, and they can be used in primary care to manage interventions personalized for every subject.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clustering of lifestyle behaviors and adiposity in early adolescents in Spain: findings from the SI! Program for Secondary Schools

  • Bodega, Patricia
  • Santos-Beneit, Gloria
  • Cos-Gandoy, Amaya de
  • Moreno, Luis A.
  • Miguel, Mercedes de
  • Orrit, Xavier
  • Tresserra-Rimbau, Anna
  • Martínez-Gómez, Jesús
  • Ramírez-Garza, Sonia L.
  • Laveriano-Santos, Emily P.
  • Arancibia-Riveros, Camila
  • Estruch, Ramón
  • Lamuela-Raventós, Rosa M.
  • Fernández-Jiménez, Rodrigo
  • Fernández-Alvira, Juan M..
Background Several unhealthy lifestyle behaviors in adolescence are often linked to overweight/obesity. Some of them may be present simultaneously, leading to combined effects on health. Therefore, the clustering of several unhealthy behaviors in adolescents might be associated with adiposity excess. Purpose To identify lifestyle patterns and analyze their association with adiposity in early adolescents. Methods A cross-sectional cluster analysis was performed in 1183 adolescents (50.5% girls) with a mean age of 12.5 (0.4) years included in the SI! Program for Secondary Schools in Spain to identify lifestyle patterns based on healthy diet, step counts, sleep time, and leisure screen time. Generalized mixed models were applied to estimate the association between lifestyle patterns and adiposity indices. Results Four lifestyle patterns were derived: Cluster 1-higher screen time and poorer diet (n = 213), Cluster 2-lower activity and longer sleepers (n = 388), Cluster 3-active and shorter sleepers (n = 280), and Cluster 4-healthiest (n = 302). Except for the number of steps (12,008 (2357) day), the lifestyle behaviors in our sample presented levels far below the recommendations, especially for sleep duration. Cluster 4 included the largest proportion of adolescents from high socioeconomic status families (47.7%) and the lowest prevalence of overweight/obesity (23.1%). Compared to Cluster 4-healthiest, adolescents in the remaining clusters presented a higher prevalence of overweight/obesity and central obesity, showing Cluster 3 the highest prevalences (PR:1.31 [95%CI: 1.31, 1.31] and PR:1.40 [95%CI: 1.33, 1.47]). Conclusions Clustering of lifestyle patterns in early adolescence allows the identification of individuals with excess adiposity, in whom health promotion strategies should be stressed, especially in socioeconomically disadvantaged groups. Trial registration Clinical Trial Registry, NCT03504059. Registered 20/04/2018—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03504059.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Body image satisfaction, food consumption, diet quality, and emotional management in adolescence: a longitudinal analysis from the SI! program for secondary schools trial

  • Bodega, Patricia
  • Fernández-Alvira, Juan M.
  • de Cos-Gandoy, Amaya
  • Moreno, Luis A.
  • de Miguel, Mercedes
  • Rodríguez, Carla
  • Martínez-Gómez, Jesús
  • Laveriano-Santos, Emily P.
  • Castro-Barquero, Sara
  • Estruch, Ramón
  • Lamuela-Raventós, Rosa M.
  • Fernández-Jiménez, Rodrigo
  • Santos-Beneit, Gloria
Background: Adolescence involves physical and psychological changes that often conflict with body ideals, potentially increasing body image (BI) dissatisfaction and unhealthy diet. The main objective was to analyze cross-sectional and longitudinal associations between BI satisfaction (BIS) and nutritional status, dietary habits (DH), and emotional management (EM) in adolescents. Methods: 1315 adolescents from the SI! Program for Secondary Schools trial reported their BIS, DH, and EM at ages 12, 14 and 16. Linear and logistic mixed models estimated the associations between BIS, food intake, diet quality, and EM. Linear and logistic mixed-effect models for repeated measures assessed mean change estimates from baseline to 2- and 4-year follow-up in food intake and EM, stratified by gender. Results: A large proportion of adolescents without excess weight were dissatisfied with their BI. BIS was significantly associated with DH, especially in boys. Body-satisfied adolescents at baseline tended to have healthier DH (diet quality index: boys 56.7 ± 13.0; girls 58.8 ± 12.7) and showed a greater improvement in diet quality at 16 years (boys 3.44 (1.50, 5.37); girls 1.85 (0.18, 3.52)). Adolescents who desired to lose weight decreased their intake of sugar-sweetened beverages, sweets, and snacks, whereas boys who desired to gain weight consumed more frequently fast food, sweets, snacks, and processed meat. Body-satisfied adolescents had higher self-esteem, and girls desiring to gain weight presented higher emotional eating. Conclusions: BIS was associated with nutritional status, and EM, showing gender differences. Overall, the desire to gain weight was associated with unhealthier DH. Educational interventions should promote self-esteem and BIS by focusing messages on healthy eating instead of body weight.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Evolution of cardiovascular risk factors in aworker cohort: a cluster analysis

  • Castel-Feced, Sara
  • Maldonado, Lina
  • Aguilar-Palacio, Isabel
  • Malo, Sara
  • Moreno-Franco, Belén
  • Mur-Vispe, Eusebio
  • Alcalá-Nalvaiz, José-Tomás
  • Rabanaque-Hernández, María José
Abstract: The identification of the cardiovascular risk factor (CVRF) profile of individual patients is key to the prevention of cardiovascular disease (CVD), and the development of personalized preventive approaches. Using data from annual medical examinations in a cohort of workers, the aim of the study was to characterize the evolution of CVRFs and the CVD risk score (SCORE) over three time points between 2009 and 2017. For descriptive analyses, mean, standard deviation, and quartile values were used for quantitative variables, and percentages for categorical ones. Cluster analysis was performed using the Kml3D package in R software. This algorithm, which creates distinct groups based on similarities in the evolution of variables of interest measured at different time points, divided the cohort into 2 clusters. Cluster 1 comprised younger workers with lower mean body mass index, waist circumference, blood glucose values, and SCORE, and higher mean HDL cholesterol values. Cluster 2 had the opposite characteristics. In conclusion, it was found that, over time, subjects in cluster 1 showed a higher improvement in CVRF control and a lower increase in their SCORE, compared with cluster 2. The identification of subjects included in these profiles could facilitate the development of better personalized medical approaches to CVD preventive measures La identificación del perfil de factores de riesgo cardiovascular (FRCV) de pacientes individuales es clave para la prevención de enfermedades cardiovasculares (ECV) y el desarrollo de enfoques preventivos personalizados. Utilizando datos de exámenes médicos anuales en una cohorte de trabajadores, el objetivo del estudio fue caracterizar la evolución de los FRCV y la puntuación de riesgo de CVD (SCORE) en tres puntos temporales entre 2009 y 2017. Para análisis descriptivos, media, desviación estándar, y se utilizaron valores de cuartiles para las variables cuantitativas, y porcentajes para las categóricas. El análisis de conglomerados se realizó utilizando el paquete Kml3D en el software R. Este algoritmo, que crea distintos grupos en función de las similitudes en la evolución de las variables de interés medidas en diferentes momentos, dividió la cohorte en 2 grupos. El grupo 1 comprendía trabajadores más jóvenes con índice de masa corporal medio, circunferencia de la cintura, valores de glucosa en sangre y SCORE más bajos, y valores medios de colesterol HDL más altos. El grupo 2 tenía las características opuestas. En conclusión, se encontró que, a lo largo del tiempo, los sujetos del grupo 1 mostraron una mayor mejora en el control de los FRCV y un menor aumento en su SCORE, en comparación con el grupo 2. La identificación de los sujetos incluidos en estos perfiles podría facilitar el desarrollo de mejores evaluaciones personalizadas. Enfoques médicos de las medidas preventivas de ECV.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation, The 2019 Expert Consensus From the Transplantion Society Working Group

  • Schinstock, Carrie A.|||0000-0002-3274-3277
  • Mannon, Roslyn B.|||0000-0003-1776-3680
  • Budde, K
  • Chong, Anita S.
  • Haas, Mark
  • Knechtle, Stuart
  • Lefaucheur, Carmen
  • Montgomery, Robert A.
  • Nickerson, Peter|||0000-0002-7393-7799
  • Tullius, Stefan G.
  • Ahn, Curie
  • Askar, Medhat
  • Crespo, Marta|||0000-0001-6992-6379
  • Chadban, Steven J.
  • Feng, Sandy
  • Jordan, Stanley C.
  • Man, Kwan
  • Mengel, Michael|||0000-0002-7222-3356
  • Morris, Randall E.
  • O'Doherty, Inish
  • Ozdemir, Binnaz H.
  • Seron, Daniel|||0000-0003-2054-653X
  • Tambur, Anat R.
  • Tanabe, Kazunari
  • Taupin, Jean-Luc
  • O'Connell, Philip J.
With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed to improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis, from the diagnostic algorithm to novel biomarkers

  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Vergara, Ander|||0000-0003-1926-0147
  • García-Carro, Clara|||0000-0002-5130-603X
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • López-Hellín, Joan|||0000-0001-7286-3882
  • Soler, María José|||0000-0003-3621-0766
Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30-50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Torres, Irina B.|||0000-0003-3304-0810
  • Sellarés, Joana
  • Chamoun, Betty|||0000-0002-4267-2273
  • Seron, Daniel|||0000-0003-2054-653X
  • Moreso, Francesc|||0000-0002-7267-3963
Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies, The Influence of TAC Exposure and Metabolism

  • Chamoun, Betty|||0000-0002-4267-2273
  • Torres, Irina B.|||0000-0003-3304-0810
  • Gabaldón, Alejandra
  • Sellarés Nadal, Joana
  • Perelló, Manel|||0000-0003-1859-5279
  • Castellà Fernández, Eva
  • Guri, Xavier
  • Salcedo, Maite
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C), coefficient of variation of tacrolimus (CV-TAC-C), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C at the time of biopsy as well as CV-TAC-C, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50-0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01-1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25-0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24-0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria

  • Moreso, Francesc|||0000-0002-7267-3963
  • Sellarès, Joana
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
The clinical significance of renal transplant biopsies displaying borderline changes suspicious for T-cell mediated rejection (TCMR) or interstitial fibrosis and tubular atrophy (IFTA) with interstitial inflammation has not been well defined. Molecular profiling to evaluate renal transplant biopsies using microarrays has been shown to be an objective measurement that adds precision to conventional histology. We review the contribution of transcriptomic analysis in surveillance and indication biopsies with borderline changes and IFTA associated with variable degrees of inflammation. Transcriptome analysis applied to biopsies with borderline changes allows to distinguish patients with rejection from those in whom mild inflammation mainly represents a response to injury. Biopsies with IFTA and inflammation occurring in unscarred tissue display a molecular pattern similar to TCMR while biopsies with IFTA and inflammation in scarred tissue, apart from T-cell activation, also express B cell, immunoglobulin and mast cell-related genes. Additionally, patients at risk for IFTA progression can be identified by genes mainly reflecting fibroblast dysregulation and immune activation. At present, it is not well established whether the expression of rejection gene transcripts in patients with fibrosis and inflammation is the consequence of an alloimmune response, tissue damage or a combination of both.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation

  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Puig-Gay, Natalia|||0000-0002-4703-0165
  • Vergara, Ander|||0000-0003-1926-0147
  • Gabaldon, Maria-Alejandra
  • Sellarés, Joana
  • Villena-Ortiz, Yolanda|||0000-0003-0925-0498
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Moreso, Francesc|||0000-0002-7267-3963
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
  • López-Hellín, Joan|||0000-0001-7286-3882
A major complication of primary focal segmental glomerulosclerosis (FSGS) is its recurrence after kidney transplantation that happens in 30 to 40% of the patients. The diagnosis of these relapses is not always easy as the histological lesions are not highly specific and appear after the proteinuria increase. Currently, there are no accurate biomarkers to detect FSGS recurrence. Our group identified a modified form of Apolipoprotein A-I (ApoA-I), named ApoA-Ib, specifically present in the urine of recurrent FSGS patients after kidney transplantation. Aberrant forms of ApoA-I have also been described in the urine of native primary FSGS patients; this feature has been associated with prominent staining of ApoA-I at the apical membrane of the tubular cells. In this study, we aim to analyze the ApoA-I distribution in kidney allograft biopsies of recurrent FSGS patients. We detected ApoA-I by immunohistochemistry in kidney allograft biopsies of patients with FSGS relapse after kidney transplantation and in kidney allograft biopsies of patients with a disease different from FSGS in the native kidney (non-FSGS). In recurrent FSGS patients, ApoA-I was prominently localized at the brush border of the tubular cells, while in the non-FSGS patients, ApoA-I was found along the cytoplasm of the tubular cells. The localization of ApoA-I at the brush border of the tubular cells is a specific feature of primary FSGS in relapse. This suggests that ApoA-I staining in kidney biopsies, coupled with ApoA-Ib measurement in urine, could be used as a diagnostic tool of primary FSGS relapse after kidney transplantation due to its highly specific tubular distribution.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

  • Herrera Arozamena, Clara
  • Estrada Valencia, Martín
  • Pérez, Concepción
  • Lagartera Ortiz, Laura
  • Morales García, Jose Ángel
  • Pérez Castillo, Ana
  • Franco Gonzalez, Juan Felipe
  • Michalska, Patrycja
  • Duarte Flórez, Pablo
  • León Martínez, Rafael
  • García López, Manuela
  • Mills Fernández, Alberto|||0000-0003-4819-1638
  • Gago Badenas, Federico|||0000-0002-3071-4878
  • García Yagüe, Ángel Juan
  • Fernández Ginés, Raquel
  • Cuadrado Pastor, Antonio
  • Rodríguez Franco, María Isabel
24 p., New multi-target indole and naphthalene derivatives containing the oxadiazolone scaffold as a bioisostere of the melatonin acetamido group have been developed. The novel compounds were characterized at melatonin receptors MT1R and MT2R, quinone reductase 2 (QR2), lipoxygenase-5 (LOX-5), and monoamine oxidases (MAO-A and MAO-B), and also as radical scavengers. We found that selectivity within the oxadiazolone series can be modulated by modifying the side chain functionality and co-planarity with the indole or naphthalene ring. In phenotypic assays, several oxadiazolone-based derivatives induced signalling mediated by the transcription factor NRF2 and promoted the maturation of neural stem-cells into a neuronal phenotype. Activation of NRF2 could be due to the binding of indole derivatives to KEAP1, as deduced from surface plasmon resonance (SPR) experiments. Molecular modelling studies using the crystal structures of QR2 and the KEAP1 Kelch-domain, as well as the recently described X-ray free-electron laser (XFEL) structures of chimeric MT1R and MT2R, provided a rationale for the experimental data and afforded valuable insights for future drug design endeavours., Ministerio de Ciencia, Innovación y Universidades, Agencia Española de Investigación, Fondo Europeo de Desarrollo Regional (FEDER), Comunidad de Madrid, Instituto de Salud Carlos III, Ministerio de Educación y Ciencia, Ministerio de Economía y Competitividad